Abstract
Earlier this year at CROI, researchers presented two phase III trials in which a fixed-dose once-daily coformulation of tenofovir/FTC/elvitegravir/cobicistat (known as “Quad”) was compared with a standard first-line regimen consisting of tenofovir/FTC/efavirenz (Atripla) or tenofovir/FTC + ritonavir-boosted atazanavir (JW AIDS Clin Care Apr 2 2012). Now, the 48-week results of these trials have been published. Treatment-naive patients (approximately 700 in each trial; about 90% men) were randomized 1:1 to receive Quad or the comparator regimen. The trials were placebo-controlled, blinded, and sponsored by the maker of Quad. Patients were required to have an estimated glomerular filtration rate (eGFR) >70 mL/minute/1.73 m2 — and, in fact, the median eGFR in both trials …
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
